Boehringer Ingelheim partners with Enleofen to develop first-in-class anti-IL-11 therapies for a range of fibrotic diseases

Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced the acquisition of worldwide exclusive rights to Enleofen's preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases. The new partnership combines Boehringer Ingelheim's leading expertise and comprehensive pipeline in fibrotic diseases with Enleofen’s world-leading expertise in IL-11 biology and the company's extensive range of therapeutic antibodies targeting this pathway.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news